270 related articles for article (PubMed ID: 25634751)
21. Preoperative serum C-reactive protein levels and post-operative lymph node ratio are important predictors of survival after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma.
Sanjay P; de Figueiredo RS; Leaver H; Ogston S; Kulli C; Polignano FM; Tait IS
JOP; 2012 Mar; 13(2):199-204. PubMed ID: 22406601
[TBL] [Abstract][Full Text] [Related]
22. Validation of the pretreatment neutrophil-lymphocyte ratio as a predictor of overall survival in a cohort of patients with pancreatic ductal adenocarcinoma.
Ben Q; An W; Wang L; Wang W; Yu L; Yuan Y
Pancreas; 2015 Apr; 44(3):471-7. PubMed ID: 25423560
[TBL] [Abstract][Full Text] [Related]
23. Paraneoplastic Ma Antigen-Like 1 as a Potential Prognostic Biomarker in Human Pancreatic Ductal Adenocarcinoma.
Kuwae Y; Kakehashi A; Wakasa K; Wei M; Yamano S; Ishii N; Ohsawa M; Wanibuchi H
Pancreas; 2015 Jan; 44(1):106-15. PubMed ID: 25251443
[TBL] [Abstract][Full Text] [Related]
24. Cyclin E expression and outcome in pancreatic ductal adenocarcinoma.
Skalicky DA; Kench JG; Segara D; Coleman MJ; Sutherland RL; Henshall SM; Musgrove EA; Biankin AV
Cancer Epidemiol Biomarkers Prev; 2006 Oct; 15(10):1941-7. PubMed ID: 17035403
[TBL] [Abstract][Full Text] [Related]
25. Ataxia-telangiectasia-mutated protein kinase levels stratify patients with pancreatic adenocarcinoma into prognostic subgroups with loss being a strong indicator of poor survival.
Kamphues C; Bova R; Bahra M; Klauschen F; Muckenhuber A; Sinn BV; Warth A; Goeppert B; Endris V; Neuhaus P; Weichert W; Stenzinger A
Pancreas; 2015 Mar; 44(2):296-301. PubMed ID: 25423555
[TBL] [Abstract][Full Text] [Related]
26. Metastatic lymph node ratio as an important prognostic factor in pancreatic ductal adenocarcinoma.
Robinson SM; Rahman A; Haugk B; French JJ; Manas DM; Jaques BC; Charnley RM; White SA
Eur J Surg Oncol; 2012 Apr; 38(4):333-9. PubMed ID: 22317758
[TBL] [Abstract][Full Text] [Related]
27. Jagged1 and DLL4 expressions in benign and malignant pancreatic lesions and their clinicopathological significance.
Huang SF; Yang ZL; Li DQ; Liu ZY; Wang CW; Miao XY; Zou Q; Yuan Y
Hepatobiliary Pancreat Dis Int; 2016 Dec; 15(6):640-646. PubMed ID: 27919854
[TBL] [Abstract][Full Text] [Related]
28. Reproducibility of tumor budding assessment in pancreatic cancer based on a multicenter interobserver study.
Karamitopoulou E; Esposito I; Zlobec I; Insilla AC; Wartenberg M; Schaeffer DF; Kalloger S; La Rosa S; Sempoux C; Ramos Centeno I; Lohneis P
Virchows Arch; 2021 Apr; 478(4):719-726. PubMed ID: 33330964
[TBL] [Abstract][Full Text] [Related]
29. Absence of FLICE-inhibitory protein is a novel independent prognostic marker for very short survival in pancreatic ductal adenocarcinoma.
Schmid SJ; Glatzel MC; Welke C; Kornmann M; Kleger A; Barth TF; Fulda S; Lennerz JK; Möller P
Pancreas; 2013 Oct; 42(7):1114-9. PubMed ID: 24005232
[TBL] [Abstract][Full Text] [Related]
30. Tumor budding is a strong and reproducible prognostic marker in T3N0 colorectal cancer.
Wang LM; Kevans D; Mulcahy H; O'Sullivan J; Fennelly D; Hyland J; O'Donoghue D; Sheahan K
Am J Surg Pathol; 2009 Jan; 33(1):134-41. PubMed ID: 18971777
[TBL] [Abstract][Full Text] [Related]
31. Loss of Raf-1 kinase inhibitory protein in pancreatic ductal adenocarcinoma.
Kim HS; Kim GY; Lim SJ; Kim YW
Pathology; 2010 Dec; 42(7):655-60. PubMed ID: 21080875
[TBL] [Abstract][Full Text] [Related]
32. Clinico-pathological characteristics and clinical outcome of different histological types of pancreatic cancer in a large Middle European series.
Stotz M; Eisner F; Szkandera J; Absenger G; Kornprat P; Lackner C; Samonigg H; Gerger A; Pichler M
J Clin Pathol; 2013 Sep; 66(9):753-7. PubMed ID: 23750038
[TBL] [Abstract][Full Text] [Related]
33. Prognostic significance of immunohistochemical RhoA expression on survival in pancreatic ductal adenocarcinoma: a high-throughput analysis.
Dittert DD; Kielisch C; Alldinger I; Zietz C; Meyer W; Dobrowolski F; Saeger HD; Baretton GB
Hum Pathol; 2008 Jul; 39(7):1002-10. PubMed ID: 18495213
[TBL] [Abstract][Full Text] [Related]
34. Can statistically determined prognostic factors predict the long-term survival of patients with pancreatic ductal adenocarcinoma following surgical resection?: Clinicopathological analysis of 82 long-term survivors.
Shin SH; Kim SC; Hong SM; Song KB; Lee JH; Park KM; Lee YJ
Pancreas; 2014 May; 43(4):571-7. PubMed ID: 24681875
[TBL] [Abstract][Full Text] [Related]
35. High c-Met expression in stage I-II pancreatic adenocarcinoma: proposal for an immunostaining scoring method and correlation with poor prognosis.
Neuzillet C; Couvelard A; Tijeras-Raballand A; de Mestier L; de Gramont A; Bédossa P; Paradis V; Sauvanet A; Bachet JB; Ruszniewski P; Raymond E; Hammel P; Cros J
Histopathology; 2015 Nov; 67(5):664-76. PubMed ID: 25809563
[TBL] [Abstract][Full Text] [Related]
36. Presence of primary cilia in cancer cells correlates with prognosis of pancreatic ductal adenocarcinoma.
Emoto K; Masugi Y; Yamazaki K; Effendi K; Tsujikawa H; Tanabe M; Kitagawa Y; Sakamoto M
Hum Pathol; 2014 Apr; 45(4):817-25. PubMed ID: 24656092
[TBL] [Abstract][Full Text] [Related]
37. Clinicopathologic features and prognostic implications of MYBL2 protein expression in pancreatic ductal adenocarcinoma.
Yu R; Li C; Lin X; Chen Q; Li J; Song L; Lin L; Liu J; Zhang Y; Kong W; Ouyang X; Chen X
Pathol Res Pract; 2017 Aug; 213(8):964-968. PubMed ID: 28559119
[TBL] [Abstract][Full Text] [Related]
38. Preoperative cognitive function predicts survival in patients with resectable pancreatic ductal adenocarcinoma.
Baekelandt BM; Hjermstad MJ; Nordby T; Fagerland MW; Kure EH; Heiberg T; Buanes T; Labori KJ
HPB (Oxford); 2016 Mar; 18(3):247-54. PubMed ID: 27017164
[TBL] [Abstract][Full Text] [Related]
39. Association of microRNA-21 expression with its targets, PDCD4 and TIMP3, in pancreatic ductal adenocarcinoma.
Nagao Y; Hisaoka M; Matsuyama A; Kanemitsu S; Hamada T; Fukuyama T; Nakano R; Uchiyama A; Kawamoto M; Yamaguchi K; Hashimoto H
Mod Pathol; 2012 Jan; 25(1):112-21. PubMed ID: 21983937
[TBL] [Abstract][Full Text] [Related]
40. CD40 expression in pancreatic cancer.
Unek T; Unek IT; Agalar AA; Sagol O; Ellidokuz H; Ertener O; Oztop I; Karademir S; Yilmaz U; Astarcioglu I
Hepatogastroenterology; 2013; 60(128):2085-93. PubMed ID: 24719952
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
